Serina Therapeutics (SER) Operating Margin (2018 - 2025)
Historic Operating Margin for Serina Therapeutics (SER) over the last 8 years, with Q2 2025 value amounting to 4280.77%.
- Serina Therapeutics' Operating Margin rose 32996200.0% to 4280.77% in Q2 2025 from the same period last year, while for Sep 2025 it was 20141.38%, marking a year-over-year decrease of 197847700.0%. This contributed to the annual value of 30442.86% for FY2024, which is 303436200.0% down from last year.
- As of Q2 2025, Serina Therapeutics' Operating Margin stood at 4280.77%, which was up 32996200.0% from 39635.71% recorded in Q4 2024.
- Serina Therapeutics' 5-year Operating Margin high stood at 39635.71% for Q4 2024, and its period low was 46420.0% during Q1 2024.
- For the 5-year period, Serina Therapeutics' Operating Margin averaged around 11522.48%, with its median value being 6975.0% (2021).
- Examining YoY changes over the last 5 years, Serina Therapeutics' Operating Margin showed a top increase of 396279100bps in 2024 and a maximum decrease of -432133300bps in 2024.
- Serina Therapeutics' Operating Margin (Quarter) stood at 6914.81% in 2021, then tumbled by -222bps to 22275.0% in 2022, then soared by 100bps to 7.81% in 2023, then soared by 507599bps to 39635.71% in 2024, then plummeted by -111bps to 4280.77% in 2025.
- Its Operating Margin stands at 4280.77% for Q2 2025, versus 39635.71% for Q4 2024 and 37942.86% for Q3 2024.